Bexarotene (BEX), a retinoid X receptor (RXR) agonist, has demonstrated therapeutic potential in oncology, neurodegenerative diseases and inflammatory conditions, including multiple sclerosis (MS). However, its broader clinical application is limited by poor aqueous solubility, low bioavailability, and dose-limiting ad...
Siân Rizzo, Carola Pepe, Thibault Albert et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.